Multiple primary lung cancer (MPLC) remains a tough challenge to diagnose and treat.
Although neoadjuvant immunotherapy has shown promising results in early stage non-small …

Background Immunotherapy has revolutionized cancer treatment, but most patients are
refractory to immunotherapy or acquire resistance, with the underlying mechanisms …

Background The clinical efficacy observed with inhibitors of programed cell death
1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to …

Background There is a paucity of biomarkers that can predict the degree of pathological
response [eg, pathological complete response (pCR) or major response (pMR)] to …

Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC)
has improved pathological responses and survival rates compared with chemotherapy …

Introduction Patients with stage II to III lung adenocarcinomas are treated with adjuvant
chemotherapy (ACT) to target the premetastatic niche that persists after curative-intent …

Purpose: Our understanding of the immunopathology of resectable non–small cell lung
cancer (NSCLC) is still limited. Here, we explore immune programs that inform of tumor …

Objectives Early stage non-small cell lung cancer (NSCLC) patients who undergo complete
resection continue to demonstrate high risk of recurrence and death. The advent of the …

The combination of immune checkpoint inhibitors (ICIs) with chemotherapy (
chemoimmunotherapy) in the neoadjuvant setting have achieved favorable clinical benefits …

The clinical outcome of resectable non–small‐cell lung cancer (NSCLC) patients receiving
neoadjuvant chemoimmunotherapy is good but varies greatly. In addition, the pathological …